Refining AML outcome prediction

Christopher S. Hourigan; Robert Peter Gale; Roland B. Walter

doi:10.1038/s41375-018-0317-4

Refining AML outcome prediction

Christopher S. Hourigan, Robert Peter Gale, Roland B. Walter

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	283-284
Number of pages	2
Journal	Leukemia
Volume	33
Issue number	2
DOIs	https://doi.org/10.1038/s41375-018-0317-4
State	Published - Feb 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-018-0317-4

Cite this

@article{b290413300344d9785e997fce17ed014,

title = "Refining AML outcome prediction",

author = "Hourigan, {Christopher S.} and Gale, {Robert Peter} and Walter, {Roland B.}",

note = "Funding Information: Acknowledgements This work was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. CSH receives research funding from Merck Sharpe & Dohme and SELLAS Life Sciences Group AG. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. RPG is a is a part-time employee of Celgene Corp. RBW is a Leukemia & Lymphoma Society Scholar in Clinical Research.",

year = "2019",

month = feb,

day = "1",

doi = "10.1038/s41375-018-0317-4",

language = "English (US)",

volume = "33",

pages = "283--284",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Refining AML outcome prediction

AU - Hourigan, Christopher S.

AU - Gale, Robert Peter

AU - Walter, Roland B.

N1 - Funding Information: Acknowledgements This work was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. CSH receives research funding from Merck Sharpe & Dohme and SELLAS Life Sciences Group AG. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. RPG is a is a part-time employee of Celgene Corp. RBW is a Leukemia & Lymphoma Society Scholar in Clinical Research.

PY - 2019/2/1

Y1 - 2019/2/1

UR - http://www.scopus.com/inward/record.url?scp=85058631723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058631723&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0317-4

DO - 10.1038/s41375-018-0317-4

M3 - Editorial

C2 - 30552400

AN - SCOPUS:85058631723

SN - 0887-6924

VL - 33

SP - 283

EP - 284

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Refining AML outcome prediction

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this